TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17015999
Drug: Sulbactam/ampicillin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/ampicillin therapy (6 g/day)
Study: 17015999
Drug: Imipenem/cilastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin therapy (1 g/day)
Study: 12787040
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral mucosa (NOM)
Study: 12787040
Drug: Friction hyperkeratosis
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friction hyperkeratosis on OSF buccal mucosa (FHOSF)
Study: 12787040
Drug: Oral leukoplakia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leukoplakia on OSF buccal mucosa (OLOSF)
Study: 9382431
Drug: Visual inspection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual inspection of the oral cavity and pharynx with flexible endoscopy and blue-toluidine staining
Study: 1420743
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg by sublingual route 5 min before the meal)
Study: 1420743
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (20 mg by sublingual route 30 min before the meal)
Study: 3900458
Drug: TMS-19-Q.GC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMS-19-Q.GC tablet (600 mg daily)
Study: 3900458
Drug: Josamycin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (1,200 mg daily)
Study: 27831987
Drug: Predictors included
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Predictors included age, lower‐most instrumented vertebra (LIV), pre‐operative sagittal vertical axis (SVA), upper‐most instrumented vertebra (UIV) implant type, UIV, pre‐operative pelvic tilt (PT), and pre‐operative pelvic incidence minus lumbar lordosis (PI-LL).
Study: 25179849
Drug: Early aggressive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early aggressive therapy
Study: 16378115
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg/kg administered before rebeat
Study: 11833860
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g sodium oxybate
Study: 11833860
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g sodium oxybate
Study: 11833860
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g sodium oxybate
Study: 7737713
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 25 mg hydrochlorothiazide once daily for 1 month
Study: 21958068
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg plus Telmisartan 80 mg
Study: 16860426
Drug: Nonoxynol-9 vaginal
Normalized name: nonoxynol-9 Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 vaginal gel (52.5mg, 3.5%)
Study: 23243245
Drug: AMP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP (5 g/kg of diet)
Study: 21308291
Drug: Identical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical treatment using distilled water as cooling liquid
Study: 11697754
Drug: Amlodipine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (dosage not specified)
Study: 7910272
Drug: Laparoscopic hernia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic hernia repair (group L) with transabdominal stapling of preperitoneal Prolene mesh.
Study: 29141079
Drug: Ocriplasmin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (125 μg, single intravitreal injection)
Study: 25957056
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral prasugrel 60 mg
Study: 25957056
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin 300 mg plus prasugrel 60 mg
Study: 19567309
Drug: Supplemental buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental buccal and lingual infiltrations of 2% lidocaine with 1:200,000 epinephrine
Study: 19567309
Drug: Supplemental buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental buccal and lingual infiltrations of 4% articaine with 1:200,000 epinephrine
Study: 9256139
Drug: CTVP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days plus pirarubicin 50 mg/m2)
Study: 9256139
Drug: CVP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days)
Study: 30392575
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily capsules of 200 mg DHA each (n=176)
Study: 30392575
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily capsules of vegetable oil without DHA (n=169)
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 12.5, 25 or 50 μg twice daily (BID) plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 25 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 50 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 12.5 μg BID
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 25 μg BID
Study: 27109816
Drug: Extrafine glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine glycopyrronium bromide (GB) 50 μg BID
Study: 22215473
Drug: Reduced-dose RCHOP
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose RCHOP chemotherapy (375 mg/m² rituximab, 600 mg/m² cyclophosphamide, 30 mg/m² doxorubicin, 1 mg vincristine, and 40 mg prednisone)
Study: 22215473
Drug: Reduced-dose RCHOP
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose RCHOP chemotherapy
Study: 18208828
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin with aspirin
Study: 16135834
Drug: Risedronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (30 mg per day for 60 days)
Study: 11812681
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% (2 mg/kg)
Study: 11812681
Drug: Bupivacaine 0.2%
Normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.2% (2 mg/kg)
Study: 10418698
Drug: D,L-fenfluramine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-fenfluramine hydrochloride (60 mg) after T-
Study: 7428409
Drug: Controlled-release aminophylline
Normalized name: aminophylline Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release aminophylline plus routine inhaled salbutamol
Study: 7428409
Drug: Controlled-release aminophylline
Normalized name: aminophylline Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release aminophylline and inhaled salbutamol on demand
Study: 7428409
Drug: Controlled-release aminophylline
Normalized name: aminophylline Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release aminophylline plus inhaled salbutamol on need
Study: 7428409
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol plus routinely inhaled salbutamol
Study: 11943957
Drug: Dioctahedral smectite
Normalized name: Dioctahedral smectite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctahedral smectite combined with hypotonic oral rehydration solution (Gastrolit)
Study: 27749549
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (mandibular angle approach)
Study: 27749549
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G
Study: 24424249
Drug: Ranibizumab PRN
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab PRN (after 6 months of sham treatment)
Study: 24424249
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment followed by ranibizumab 0.5 mg PRN
Study: 22212377
Drug: PUFA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA 4 g daily for 12 weeks
Study: 20339140
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide acetate (LAO) 30 mg via intramuscular injection, given 4-7 days before radiation and on day 22 of treatment.
Study: 20339140
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given 4-7 days before radiation and on day 22 of treatment.
Study: 15323164
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (at least one course)
Study: 8675251
Drug: High insulinemia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High insulinemia (287 pmol/L)
Study: 1999687
Drug: Beta-carotene (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (10 mg daily for 3 months)
Study: 1999687
Drug: Total intake
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intake of beta-carotene (diet + medication)
Study: 6095660
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg taken orally at night for 12 months
Study: 6095660
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg taken orally at night for 12 months
Study: 15338805
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of testosterone, intra-muscularly, every fourth week for 26 weeks
Study: 8277078
Drug: SHU 508A
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SHU 508A (200 mg/ml in 5 ml, 200 mg/ml in 10 ml, 300 mg/ml in 5 ml, 300 mg/ml in 10 ml)
Study: 2551411
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (5.4 g eicosapentaenoic acid and 3.6 g docosahexaenoic acid)
Study: 786670
Drug: Nomifensin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensin (average daily dose 84 mg)
Study: 786670
Drug: Desimipramine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desimipramine (average daily dose 76 mg)
Study: 29308523
Drug: 100 g-force
Normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 19 g in 100 g TOPICAL STICK [Brut Arctic Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g-force
Study: 29308523
Drug: 150 g-force
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g-force
Study: 29308523
Drug: 200 g-force
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g-force
Study: 23668634
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg
Study: 23668634
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 50 mg and 500 mg
Study: 20855554
Drug: Shockwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shockwave therapy (SWT) - 2500 impulses per session at 0.18 mJ/mm² energy flux density for 4 weeks
Study: 20855554
Drug: Traditional conservative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional conservative treatment (TCT) - nonsteroidal anti-inflammatory drugs, physiotherapy, and an exercise program for hamstring muscles for 4 weeks
Study: 17766923
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice daily for 6 months
Study: 17766923
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in obese women
Study: 11137806
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with cholesterol <4.7mmol/l (group 3)
Study: 9505749
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (5 ml infiltrated along the scrotal incision and 1 ml injected into the vas deferens)
Study: 7881986
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (oral or intravenous)
Study: 2119396
Drug: Sprinkle capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkle capsules
Study: 2119396
Drug: Sprinkle capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkle capsules (fasting)
Study: 2119396
Drug: Enteric-coated tablets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablets (fasting)
Study: 2119396
Drug: Sprinkle capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkle capsules (nonfasting)
Study: 322267
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 600 mg administered as three divided doses with meals for one week.
Study: 322267
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 3 g administered as three divided doses with meals for one week.
Study: 11152249
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen (4 L min(‐1))
Study: 11152249
Drug: Air (21%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (21% oxygen, 4 L min(‐1))
Study: 9091710
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection (prilocaine/etidocaine mixture)
Study: 9091710
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection
Study: 1301126
Drug: Hospital-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based treatment (H)
Study: 3905773
Drug: Methylphenidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (up to 60 mg/day)
Study: 29699021
Drug: Ulinastatin 100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin 100,000 u intravenous injection every 8 hours for 7 days
Study: 29699021
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with hyperbaric oxygen and routine medical treatment
Study: 23183990
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment program
Study: 17785618
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 to 75 mg orally 3 times daily)
Study: 15932791
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg four times a day
Study: 17557
Drug: Penbutolol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (8 mg to 50 mg per day)
Study: 27837709
Drug: Comprehensive geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive geriatric assessment (CGA) including medication assessment annually between 2004 and 2007
Study: 3538753
Drug: Femoxetine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (200 mg increasing to 600 mg daily over 9 days)
Study: 28532406
Drug: Vildagliptin/Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/Metformin therapy (n = 40)
Study: 28532406
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (n = 20)
Study: 27128001
Drug: Ketoconazole (strong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (strong CYP3A4 inhibitor)
Study: 27128001
Drug: Azithromycin (weak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (weak CYP3A4 inhibitor)
Study: 27128001
Drug: Alisporivir (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (as an inhibitor of CYP3A4)
Study: 21146637
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Simvastatin
Study: 16934158
Drug: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at 12-hour intervals for 24 hours
Study: 16934158
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP l) administered at 24-hour intervals for 3 days
Study: 16934158
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (AS+SMP f and AS+SMP l)
Study: 10633973
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for one week and 40 mg/day thereafter (group I)
Study: 10633973
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day (group II)
Study: 10633973
Drug: Fluoxetine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (group I)
Study: 10633973
Drug: Sertraline (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (group II)
Study: 8607401
Drug: Quinapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (5 to 10 mg/day)
Study: 8607401
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 to 100 mg/day)
Study: 1901181
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate tablets
Study: 30586694
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg once daily for 16 weeks
Study: 28765326
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) monotherapy (75 mg/m2 × 7 days every 28 days)
Study: 28765326
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) combined with Vorinostat (VOR) (300 mg twice a day on days 3 to 9)
Study: 21507715
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib (1.3 mg/m2, twice per week)
Study: 21507715
Drug: Intravenous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bortezomib (1.3 mg/m2, twice per week)
Study: 11993078
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve blockade (ICB) with ropivacaine 1% (4 times 5 ml)
Study: 11993078
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with 7.5 mg piritramid i.v. before extubation and continuing with 2 mg boli and a 10 min lockout
Study: 8553906
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2 (18 million IU/day subcutaneously for 3 days)
Study: 8553906
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (6 million IU/day subcutaneously for 5 days) plus MLT (40 mg/day orally)
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 30 mg
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 60 mg
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 15 mg (four times daily)
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 30 mg (four times daily)
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (various doses)
Study: 30669825
Drug: Schroth therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schroth therapy
Study: 29125382
Drug: Intra-sheath injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Study: 29125382
Drug: Extra-sheath injection
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-sheath injection of 1ml of 40mg/ml methyl prednisolone acetate
Study: 25984794
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) after 8 sessions